Unity Biotechnology
2009
FOUNDED
PUBLIC
STATUS
101-200
EMPLOYEES
UBX
STOCK SYMBOL
$6.96
SHARE PRICE
(As of Thursday Closing)
Description
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as arthritis, vision loss and cognitive decline.
Website
Formerly Known As
Cenexys
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 3280 Bayshore Boulevard
- Brisbane, CA 94005
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Unity Biotechnology’s full profile, request a free trial.
Unity Biotechnology Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $5.61 - $12.29 | $320M | $7.06 | -$2.04 | 219K | 45.9M |
Unity Biotechnology Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 135,537 | 510,351 | ||
| Revenue | 0 | 0 | 1,382 | 0 |
| EBITDA | (87,281) | (77,530) | (44,407) | (28,068) |
| Net Income | (86,066) | (76,398) | (44,656) | (30,404) |
| Total Assets | 141,678 | 181,375 | 102,024 | 96,648 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Unity Biotechnology Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Unity Biotechnology‘s full profile, request access.
Request full access to PitchBookUnity Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Unity Biotechnology‘s full profile, request access.
Request full access to PitchBookUnity Biotechnology Competitors (3)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Recyte Therapeutics | Angel-Backed | Alameda, CA | 000.00 | 0000000000 | 000.00 | |
| 000000000 | Formerly VC-backed | Boston, MA | 00 | 00000 | 000000 - 000 | 00000 |
| 000000 | Corporation | Honolulu, HI | 00 | 000.00 | 000000000 | 000.00 |
Unity Biotechnology Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Unity Biotechnology‘s full profile, request access.
Request full access to PitchBookUnity Biotechnology Executive Team (21)
3 Former Executives
You’re viewing 5 of 21 executives. Get the full list »Unity Biotechnology Board Members (9)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Camille Samuels | Venrock | Board Member | 000 0000 | |
| David Lacey MD | Self | Board Member | 000 0000 | |
| Graham Cooper | Self | Board Member | 000 0000 | |
| Keith Leonard Jr. | Unity Biotechnology | Chief Executive Officer & Chairman | 000 0000 | |
| Kristina Burow | ARCH Venture Partners | Board Member | 000 0000 |